The most frequent grade @-@ adverse events included diarrhoea ( @ -LSB- @ % -RSB- of @ patients in the ipilimumab group vs seven -LSB- @ % -RSB- of @ in the placebo group ) , fatigue ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , anaemia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and colitis ( @ -LSB- @ % -RSB- vs @ ) .